Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Cincinnati, Ohio 45229


Purpose:

The research is being conducted to develop new imaging methods that are sufficiently sensitive to allow for early diagnosis of BOS, a chronic allograft rejection affecting 50-60% of lung transplanted recipients who survive 5 years after transplant. Although lung transplantation has evolved into an effective therapeutic option for a large number of pediatric patients with end-stage pulmonary disease, long-term survival after lung transplantation is far worse than after the transplantation of other solid organs. This research may improve patient outcomes through earlier diagnosis of changes leading to BOS by obtaining image guided research biopsies of transplanted lung. Biopsies may be used for future research of ex vivo biomarkers of BOS and in the development of treatments through future clinical trials.


Study summary:

This protocol aims to - Develop new imaging methods that are sufficiently sensitive to allow early diagnosis of BOS. - Improve patient treatment outcomes through earlier diagnosis of changes leading to BOS by obtaining image guided biopsies of transplanted lung. - Provide image guided biopsies for use in future research of ex vivo biomarkers of BOS and in the development of treatments through future clinical trials. The study will achieve these aims through a prospective, non-randomized, longitudinal, observational study that will recruit about 5 subjects a year for 5 years. The study will follow these post lung transplant patients at 6 months and 1 year with 129Xe MRI (Hyperpolarized 129Xenon Magnetic Resonance Imaging) and image guided bronchial biopsies to detect early BOS and to better understand BO disease progression. The biopsies will provide future research for rapid determination of cellular and molecular mechanisms that lead to BOS and to facilitate identification and validation of translatable pharmaceutical targets.


Criteria:

Inclusion Criteria: - Lung Transplantation within the last 10 years or being assessed for possible lung transplantation. - Participant must be able to hold their breath for up to 16 seconds. Exclusion Criteria: - Standard MRI exclusion criteria - Bleeding disorders - Participant is claustrophobic or otherwise unable to tolerate the imaging - Pregnancy or positive pregnancy test - Symptoms of respiratory infection within the past two weeks. - Baseline oximetry at MRI visit of less than 95% on room air or less than 95% on a previously prescribed dosage of oxygen delivered by nasal cannula.


NCT ID:

NCT03603899


Primary Contact:

Principal Investigator
Jason Woods, PhD
Children's Hospital Medical Center, Cincinnati

Erin Watters
Phone: 513-803-7024
Email: Erin.Watters@cchmc.org


Backup Contact:

N/A


Location Contact:

Cincinnati, Ohio 45229
United States

Jason Woods, PhD
Phone: 513-803-4463
Email: jason.woods@cchmc.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.